Replimune Group, Inc. 6,923,000 Shares of Common Stock Pre-Funded Warrants to Purchase 3,846,184 Shares of Common Stock Underwriting AgreementUnderwriting Agreement • November 27th, 2024 • Replimune Group, Inc. • Biological products, (no disgnostic substances) • New York
Replimune Group, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to Leerink Partners LLC (the “Underwriter”) an aggregate of 6,923,000 shares (the “Underwritten Shares”) of common stock, par value $0.001 per share, of the Company (the “Common Stock”), pre-funded warrants to purchase an aggregate of 3,846,184 shares of Common Stock in a form to be mutually agreed by the Company and the Underwriter (the “Warrants”) and, at the option of the Underwriter, up to an additional 1,615,377 shares of Common Stock (the “Option Shares”). The Underwritten Shares and the Warrants are herein referred to as the “Underwritten Securities”. The Underwritten Shares and the Option Shares are herein referred to as the “Shares”. The shares of Common Stock issuable upon exercise of the Warrants are herein referred to as the “Warrant Shares”. The Shares and Warrants are herein referred to as the “Securities”. The shares of Common Stock to be outstanding after giving effect to the sale
